Live tape.Join the lounge

Research with context.

A clearer way to explore the market.

Create an account Contact the team

Market signals, research, watchlists, and alerts in one workspace.

Follow the signal.

Product Pricing FAQ

Data coverage Methodology Disclosures Contact

© 2026 Longbrunch. All rights reserved.

longbrunch/

RIGL/Research

Fundamentals

RIGEL PHARMACEUTICALS INC · Equity

Partial coverage

TradeShort termMedium termLong term

Financial health Growth Valuation Profitability Shareholder return

Financial health

2 current metrics

Total Assets2026-03-31: $504.61M
Total Liabilities2026-03-31: $104.71M

Historical trendData pending

Growth

4 current metrics

Eps2026-07-31: 19.29
Free Cash Flow2026-07-31: $78.55M
Net Income2026-03-31: $8.65M
Revenue2026-03-31: $58.82M

Historical trendData pending

Valuation

3 current metrics

Market Cap2026-07-31: $681.06M
Trailing Pe2026-07-31: 1.9082426
Trailing P/E: 1.91

Historical trendData pending

Profitability

3 current metrics

Ebitda2026-07-31: $126.99M
Gross Profit2026-03-31: $54.21M
Operating Income2026-03-31: $11.89M

Historical trendData pending

Shareholder return

3 current metrics

Payout Ratio2026-07-31: 0%
Trailing Annual Dividend Rate2026-07-31: 0.0
Trailing Annual Dividend Yield2026-07-31: 0%

Historical trendData pending

Financial evidence

Statement-level periods and line items live in the dedicated view.

Open Financial Statements →